دورية أكاديمية
Impact of single-room contact precautions on acquisition and transmission of vancomycin-resistant enterococci on haematological and oncological wards, multicentre cohort-study, Germany, January-December 2016.
| العنوان: | Impact of single-room contact precautions on acquisition and transmission of vancomycin-resistant enterococci on haematological and oncological wards, multicentre cohort-study, Germany, January-December 2016. |
|---|---|
| المؤلفون: | Biehl LM; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.; German Centre for Infection Research, partner site Bonn-Cologne, Germany., Higgins PG; German Centre for Infection Research, partner site Bonn-Cologne, Germany.; Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Stemler J; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.; German Centre for Infection Research, partner site Bonn-Cologne, Germany., Gilles M; Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Peter S; Institute of Medical Microbiology and Hygiene, University of Tübingen, Tübingen, Germany.; German Centre for Infection Research, partner site Tübingen, Germany., Dörfel D; Department of Haematology, Oncology and Immunology, Siloah hospital, Hannover, Germany., Vogel W; Department of Oncology, Haematology, Immunology and Rheumatology, Internal Medicine II, University Hospital Tübingen, Tübingen, Germany., Kern WV; Division of Infectious Diseases, Department of Medicine II, University Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Gölz H; Institute for Medical Microbiology and Hygiene, University Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Bertz H; Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Rohde H; Institute for Medical Microbiology, Virology and Hygiene, University Medical Centre Hamburg-Eppendorf, Germany.; German Centre for Infection Research, partner site Hamburg-Lübeck-Borstel, Germany., Klupp EM; Institute for Medical Microbiology, Virology and Hygiene, University Medical Centre Hamburg-Eppendorf, Germany., Schafhausen P; Department of Oncology and Haematology, Hubertus Wald Tumorzentrum/University Cancer Centre Hamburg, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Salmanton-García J; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Stecher M; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.; German Centre for Infection Research, partner site Bonn-Cologne, Germany., Wille J; Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Liss B; Department I of Internal Medicine, Helios University Hospital Wuppertal, Wuppertal, Germany.; Department of Internal medicine I, School of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany., Xanthopoulou K; Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Zweigner J; Department of Hospital Hygiene and Infection Control, University Hospital of Cologne, Cologne, Germany.; Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Seifert H; German Centre for Infection Research, partner site Bonn-Cologne, Germany.; Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Vehreschild MJGT; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.; Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.; German Centre for Infection Research, partner site Bonn-Cologne, Germany. |
| المصدر: | Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2022 Jan; Vol. 27 (2). |
| نوع المنشور: | Journal Article; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: European Centre for Disease Prevention and Control (ECDC) Country of Publication: Sweden NLM ID: 100887452 Publication Model: Print Cited Medium: Internet ISSN: 1560-7917 (Electronic) Linking ISSN: 1025496X NLM ISO Abbreviation: Euro Surveill Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Stockholm, Sweden : European Centre for Disease Prevention and Control (ECDC) Original Publication: Saint-Maurice : Hôpital national de Saint-Maurice |
| مواضيع طبية MeSH: | Cross Infection*/epidemiology , Cross Infection*/prevention & control , Gram-Positive Bacterial Infections*/epidemiology , Gram-Positive Bacterial Infections*/prevention & control , Vancomycin-Resistant Enterococci*/genetics, Cohort Studies ; Humans ; Multilocus Sequence Typing ; Prospective Studies |
| مستخلص: | BackgroundEvidence supporting the effectiveness of single-room contact precautions (SCP) in preventing in-hospital acquisition of vancomycin-resistant enterococci (haVRE) is limited.AimWe assessed the impact of SCP on haVRE and their transmission.MethodsWe conducted a prospective, multicentre cohort study in German haematological/oncological departments during 2016. Two sites performed SCP for VRE patients and two did not (NCP). We defined a 5% haVRE-risk difference as non-inferiority margin, screened patients for VRE, and characterised isolates by whole genome sequencing and core genome MLST (cgMLST). Potential confounders were assessed by competing risk regression analysis.ResultsWe included 1,397 patients at NCP and 1,531 patients at SCP sites. Not performing SCP was associated with a significantly higher proportion of haVRE; 12.2% (170/1,397) patients at NCP and 7.4% (113/1,531) patients at SCP sites (relative risk (RR) 1.74; 95% confidence interval (CI): 1.35-2.23). The difference (4.8%) was below the non-inferiority margin. Competing risk regression analysis indicated a stronger impact of antimicrobial exposure (subdistribution hazard ratio (SHR) 7.46; 95% CI: 4.59-12.12) and underlying disease (SHR for acute leukaemia 2.34; 95% CI: 1.46-3.75) on haVRE than NCP (SHR 1.60; 95% CI: 1.14-2.25). Based on cgMLST and patient movement data, we observed 131 patient-to-patient VRE transmissions at NCP and 85 at SCP sites (RR 1.76; 95% CI: 1.33-2.34).ConclusionsWe show a positive impact of SCP on haVRE in a high-risk population, although the observed difference was below the pre-specified non-inferiority margin. Importantly, other factors including antimicrobial exposure seem to be more influential. |
| References: | JAMA. 2013 Oct 16;310(15):1571-80. (PMID: 24097234) J Clin Microbiol. 2016 Dec;54(12):2874-2881. (PMID: 27558178) Am J Infect Control. 2009 Mar;37(2):85-93. (PMID: 19249637) Infection. 2019 Feb;47(1):7-11. (PMID: 30178076) Antimicrob Agents Chemother. 2002 Jun;46(6):1619-28. (PMID: 12019066) MMWR Recomm Rep. 1995 Sep 22;44(RR-12):1-13. (PMID: 7565541) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004 Jan;47(1):51-61. (PMID: 15205824) Lancet Infect Dis. 2019 Apr;19(4):410-418. (PMID: 30858014) N Engl J Med. 2011 Apr 14;364(15):1407-18. (PMID: 21488763) JAMA Intern Med. 2019 Nov 1;179(11):1501-1506. (PMID: 31424489) Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S54-S62. (PMID: 30895215) N Engl J Med. 2000 Dec 28;343(26):1925-32. (PMID: 11136263) Infection. 2012 Dec;40(6):613-9. (PMID: 22665143) J Clin Microbiol. 2015 Dec;53(12):3788-97. (PMID: 26400782) J Hosp Infect. 2011 Mar;77(3):282-3. (PMID: 21288596) Open Forum Infect Dis. 2019 Mar 15;6(4):ofz139. (PMID: 31024976) Antimicrob Agents Chemother. 1996 Jun;40(6):1526-30. (PMID: 8726031) Antimicrob Agents Chemother. 2013 Jan;57(1):49-55. (PMID: 23070173) Infection. 2014 Dec;42(6):1013-22. (PMID: 25143193) Infect Control Hosp Epidemiol. 2011 May;32(5):490-6. (PMID: 21515980) Antimicrob Resist Infect Control. 2018 Apr 24;7:54. (PMID: 29760912) Am J Infect Control. 2018 Mar;46(3):333-340. (PMID: 29031432) Antimicrob Agents Chemother. 2019 Apr 25;63(5):. (PMID: 30782988) J Antimicrob Chemother. 2019 Jul 1;74(7):1776-1785. (PMID: 30929020) J Hosp Infect. 2010 Oct;76(2):97-102. (PMID: 20619929) Infect Drug Resist. 2015 Jul 24;8:217-30. (PMID: 26244026) |
| فهرسة مساهمة: | Keywords: immunocompromised host; infection control; molecular epidemiology; single room contact precautions; transmission; vancomycin-resistant enterococci |
| تواريخ الأحداث: | Date Created: 20220114 Date Completed: 20220308 Latest Revision: 20220308 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8759111 |
| DOI: | 10.2807/1560-7917.ES.2022.27.2.2001876 |
| PMID: | 35027104 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1560-7917 |
|---|---|
| DOI: | 10.2807/1560-7917.ES.2022.27.2.2001876 |